Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merz Pharmaceuticals GmbH
The study consists of a randomized, double-blind, placebo-controlled, parallel-group, single-dose main period followed by an open-label, non-controlled, repeated-dose extension period (Open-Label Extension Period - OLEX).
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Upper limb spasticity
Time since stroke greater than 3 months
Need for 400 U Botulinum toxin type A
You may not be if
Body weight below 50kg
Fixed contractures of the upper limb
Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin Type A
Infection at the injection site
Clareo Health | Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
